Open house Arzneimittelrabattverträge Pomalidomid, ATC L04AX06
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Pomalidomid, ATC L04AX06
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or budget is disclosed. The actual uptake and revenue are unknown.
If a nationwide or regional discount agreement for the same substance enters into force, the open-house agreements are...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2026
- Non-exclusive discount agreements for the active substance Pomalidomid (ATC L04AX06).
- Contracts are in accordance with §130a Abs. 8 SGB V.
Show full summary
This is an open-house model (non-competitive) for non-exclusive discount agreements on Pomalidomid (ATC L04AX06) by AOK Bayern. All qualified pharmaceutical companies can join. Contracts run from 01.10.2024 to 30.09.2026. No estimated value is provided. Eligibility requires a self-declaration of reliability. Submission can be in paper (two originals) or electronically with a qualified electronic signature. Documents must be requested via the DTVP portal.
Risks
No estimated value or budget is disclosed. The actual uptake and revenue are unknown.
If a nationwide or regional discount agreement for the same substance enters into force, the open-house agreements are...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company.
Administrative
- Submit signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed self-declaration of reliability.
- Submission either in paper form (two originals) or electronically with a qualified electronic signature.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Pomalidomid, ATC L04AX06
Non-exclusive discount agreements for Pomalidomid, ATC L04AX06, for patients of AOK Bayern. Open to all pharmaceutical companies that meet eligibility criteria.
Location
Duration
Category
Deadline
Award details
Selection criteria
Value note
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 15 Aug 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 492240-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or budget is disclosed. The actual uptake and revenue are unknown.
If a nationwide or regional discount agreement for the same substance enters into force, the open-house agreements are...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications